BRISTOL-MYERS SQUIBB COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.49 USD | -1.82% |
|
-6.62% | -21.09% |
| 05-28 | Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License | MT |
| 05-27 | Bristol Myers: will present data on schizophrenia | CF |
Presenter SpeechMichael Schmidt (Analysts)All righty, Ben. Let's continue here with Ben Hickey...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.24
USD
Average target price
53.19
USD
Spread / Average Target
+28.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.09% | 83.6B | |
| +38.59% | 727B | |
| -7.89% | 354B | |
| +15.66% | 328B | |
| +0.24% | 277B | |
| +13.47% | 243B | |
| +7.35% | 205B | |
| -6.42% | 203B | |
| +4.23% | 164B | |
| -1.70% | 164B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Transcript : Bristol-Myers Squibb Company Presents at Guggenheim Securities Radiopharmaceuticals Day, May-13-2024 11
